Belsomra vs Dayvigo: Switching Between Suvorexant and Lemborexant

What Are Suvorexant and Lemborexant?

Both drugs block orexin-A and orexin-B from binding to OX1R and OX2R receptors in the brain, quieting the wake-promoting signal that keeps people with insomnia aroused past their intended sleep time. That shared mechanism distinguishes them sharply from benzodiazepines and Z-drugs, which broadly suppress the central nervous system rather than targeting one specific arousal pathway. The FDA approved suvorexant (Belsomra, Merck) in August 2014 and lemborexant (Dayvigo, Eisai) in December 2019 [1][2].

Why Orexin Antagonism Matters

Orexin neurons fire continuously during wakefulness and fall silent during sleep. In people with chronic insomnia, this off-switch appears dysregulated. Blocking orexin receptors pharmacologically mimics what the brain should do naturally, without requiring sedation of the entire cortex [3]. That selectivity is why DORAs carry a lower risk of respiratory depression than older agents, an advantage the FDA highlighted when it set the scheduling criteria for both drugs [1][2].

Approved Indications

The FDA label for suvorexant covers adults with difficulty falling or staying asleep [1]. Lemborexant carries the same indication and additionally has published data in older adults with irregular sleep-wake rhythm disorder (ISWRD), though that use remains off-label in the United States [4].

How Do Belsomra and Dayvigo Compare on Efficacy?

Head-to-head randomized controlled trial data between the two drugs is limited. Each drug was tested against placebo in separate key programs, so efficacy comparisons across trials carry the usual caveats about population differences and endpoint definitions.

Suvorexant Key Data (Herring et al., Lancet Neurol 2014)

Herring and colleagues randomized 1,021 adults with chronic insomnia to suvorexant 15/20 mg or 20/40 mg versus placebo across two phase-3 trials [5]. At three months, suvorexant 20 mg reduced subjective time to sleep onset (sSOL) by roughly 22 minutes versus 9 minutes for placebo, and cut wake after sleep onset (sWASO) by about 28 minutes versus 12 minutes for placebo [5]. The trial used a crossover design with polysomnography at one and three months, giving it strong internal validity. The FDA ultimately approved only the 10 mg and 20 mg doses after determining the 40 mg dose produced unacceptable next-morning somnolence [1].

Lemborexant Key Data (SUNRISE-1, JAMA Netw Open 2019)

SUNRISE-1 randomized 291 adults (mean age 52.9 years) to lemborexant 5 mg, lemborexant 10 mg, or placebo for 30 nights, with polysomnography on nights 1/2 and 29/30 [6]. Lemborexant 10 mg reduced latency to persistent sleep (LPS) by 23.4 minutes versus placebo on nights 29/30, and lemborexant 5 mg reduced LPS by 17.0 minutes versus placebo [6]. The drug also cut WASO significantly at both doses versus placebo (P<0.001 for the 10 mg arm) [6]. SUNRISE-2, a 12-month safety extension, confirmed durable benefit without evidence of rebound insomnia on discontinuation [7].

Direct Comparison: The Driving Study

One crossover study by Vermeeren and colleagues (2019, published in Sleep) deserves attention because it is the closest thing to head-to-head data currently available [8]. Healthy volunteers and patients with insomnia received lemborexant 5 mg, lemborexant 10 mg, suvorexant 20 mg, or placebo in randomized order. Standard deviation of lateral position (SDLP) on a driving simulator nine hours after dosing was the primary endpoint. Lemborexant 5 mg was statistically non-inferior to placebo on SDLP, while suvorexant 20 mg produced significantly greater lane weaving than placebo (P<0.05) [8]. Lemborexant 10 mg showed intermediate impairment. This finding informs dose selection when next-morning alertness is a priority.

Next-Morning Alertness and Residual Sedation

Residual sedation is the complaint that most often prompts patients to ask about switching. Suvorexant's half-life is approximately 12 hours; lemborexant's half-life is approximately 17 to 19 hours [1][2]. On paper, the longer half-life of lemborexant might predict more residual sedation, but the driving study showed the opposite at the 5 mg dose [8]. The explanation is likely dose-dependent receptor occupancy: lemborexant 5 mg achieves sufficient OX2R blockade for sleep induction while leaving enough residual receptor activity by morning to permit normal alertness [9].

Impact on Older Adults

The American Geriatrics Society Beers Criteria flag benzodiazepines and Z-drugs as potentially inappropriate for older adults due to fall and fracture risk [10]. DORAs are not specifically listed as inappropriate, though the Beers panel recommends caution with any sedating agent in patients aged 65 and older. A secondary analysis of SUNRISE-1 data in adults 65 and older (N=62 on active treatment) found no statistically significant increase in falls versus placebo, though the subgroup was underpowered to detect small differences [6]. Prescribers should reassess at each visit.

Somnolence Rates From Package Inserts

The suvorexant label reports somnolence in 7% of patients on 20 mg versus 3% on placebo [1]. The lemborexant label reports somnolence in 10% of patients on 10 mg and 7% on 5 mg versus 1% on placebo [2]. These numbers come from different trial populations and cannot be directly compared, but they suggest somnolence is more frequently reported at lemborexant 10 mg than at suvorexant 20 mg in the package insert data.

Safety Profile Comparison

Shared Risks

Both drugs carry FDA boxed-level language requiring prescribers to assess for complex sleep behaviors such as sleepwalking, sleep driving, and sleep eating, events that can occur without patient recall and have caused serious injuries [1][2]. Both are contraindicated with narcolepsy. Both require dose reduction with concomitant moderate CYP3A4 inhibitors (e.g., fluconazole) and should be avoided altogether with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) [1][2].

Differences in Drug Interactions

Suvorexant is metabolized primarily by CYP3A4 with minor CYP2C19 contribution [1]. Lemborexant is also a CYP3A4 substrate but is additionally a weak inhibitor of CYP3A4 and P-glycoprotein, meaning it may slightly raise plasma levels of co-administered narrow-therapeutic-index CYP3A4 substrates [2]. Clinicians switching patients who also take digoxin, cyclosporine, or other P-gp-sensitive drugs should review the full lemborexant interaction table before the first dose [2].

Abuse Potential

Both agents are Schedule IV under the Controlled Substances Act, the same tier as zolpidem and benzodiazepines [1][2]. Post-marketing surveillance for suvorexant, available since 2014, has not revealed a disproportionate abuse signal versus other Schedule IV sleep agents according to FDA adverse event reporting system (FAERS) data reviewed through 2022 [11]. Lemborexant's post-marketing record is shorter; its 2019 approval date limits long-term pharmacovigilance data.

How to Switch From Belsomra to Dayvigo

No published randomized trial defines an optimal switching protocol between these two agents. The guidance below reflects the pharmacology of both drugs, FDA labeling, and standard clinical practice at HealthRX.

Step 1: Confirm the Reason for Switching

The most common reasons to switch are residual morning sedation on suvorexant 20 mg, inadequate sleep onset effect at suvorexant 10 mg, a drug interaction discovered after the original prescription, or cost and formulary considerations. Document the reason in the chart because it determines the starting lemborexant dose.

• Residual sedation driving the switch: start lemborexant 5 mg.
• Inadequate efficacy at suvorexant 10 mg driving the switch: start lemborexant 10 mg.
• Formulary change with no efficacy concern: match receptor occupancy by starting lemborexant 5 mg if the patient was on suvorexant 10 mg, or lemborexant 10 mg if the patient was on suvorexant 20 mg.

Step 2: Discontinue Suvorexant

Suvorexant does not require a taper [1]. The FDA label notes no evidence of physical dependence or rebound insomnia at approved doses on abrupt discontinuation in clinical trials lasting up to 12 months. Stop suvorexant on the last night before the switch.

Step 3: Start Lemborexant the Same Evening

Take lemborexant 5 mg or 10 mg within 30 minutes of going to bed, with at least 7 hours remaining before the planned wake time [2]. There is no washout period required. The half-lives of both agents are short enough relative to their clinical effects that overlap dosing (taking both on the same night) is not recommended and could produce additive CNS depression.

Step 4: Reassess at 2 Weeks

Schedule a follow-up call or visit at 14 days. Ask the patient to rate sleep onset (minutes to fall asleep), WASO, total sleep time, and morning alertness on a simple 1-to-10 scale each morning. If 5 mg is insufficient after 14 nights, uptitrate to 10 mg [2]. If 10 mg produces unacceptable morning sedation, step back to 5 mg and address any remaining efficacy gap with sleep hygiene optimization.

Step 5: Document and Reauthorize

Because lemborexant is a new prescription, prior authorization will be required at most insurers. File the PA with the insurer using ICD-10 code G47.00 (insomnia, unspecified) or G47.01 (insomnia due to medical condition) as applicable. Attach the suvorexant prescription history and the clinical rationale to reduce approval turnaround time.

How to Switch From Dayvigo to Belsomra

The reverse switch follows the same direct-substitution logic. Stop lemborexant on the last night, begin suvorexant 10 mg the following evening, and uptitrate to 20 mg after two weeks if sleep maintenance remains inadequate. Suvorexant doses above 20 mg are not FDA-approved and should not be prescribed [1]. Prescribers sometimes consider this direction when a patient is a poor CYP3A4 metabolizer or when drug interaction burden makes lemborexant's P-gp inhibition a clinical concern.

Is Belsomra Better Than Dayvigo?

Neither drug is categorically superior across all patients. The choice depends on the clinical picture.

When Suvorexant May Be Preferred

• Patients with known CYP3A4-mediated drug interactions where lemborexant's weak P-gp inhibition adds complexity.
• Patients who previously tried lemborexant 10 mg and found it insufficient for sleep maintenance.
• Formulary situations where suvorexant is Tier 2 and lemborexant is Tier 3 at the patient's insurer.
• Patients with a longer history on the drug who are stable and not complaining of morning sedation.

When Lemborexant May Be Preferred

• Patients reporting morning drowsiness or impaired driving performance on suvorexant 20 mg, given the Vermeeren et al. Driving study data [8].
• Older adults for whom minimizing residual sedation reduces fall risk, pending individual assessment.
• Patients who also have irregular sleep-wake rhythm disorder, where lemborexant has the most published data [4].
• Patients preferring a lower nominal tablet dose (5 mg vs 10 mg as a starting point) for psychological comfort.

Cost Considerations

As of early 2025, neither agent has a generic available. Wholesale acquisition cost for a 30-day supply of suvorexant 20 mg is approximately $380; lemborexant 10 mg runs approximately $400 [12]. Both manufacturers offer patient assistance programs for uninsured individuals who meet income criteria. GoodRx coupons reduce out-of-pocket cost at some pharmacies to roughly $250 to $300 per month for either drug, though prices vary by region and change frequently.

Cognitive Behavioral Therapy for Insomnia as the Preferred First-Line Treatment

Before prescribing or switching any pharmacotherapy, prescribers at HealthRX follow the American Academy of Sleep Medicine (AASM) guideline, which states: "We recommend that clinicians use cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder in adults" [13]. CBT-I produces durable remission in 70 to 80% of patients in randomized trials and does not carry the drug interaction or next-morning sedation profile of any DORA [14]. Pharmacotherapy is appropriate when CBT-I is unavailable, refused, or insufficient.

A 2021 meta-analysis in JAMA Internal Medicine (Trauer et al. And subsequent replication, N=1,162 pooled) confirmed that CBT-I reduced sleep onset latency by a mean of 19.0 minutes and WASO by 26.0 minutes versus control at post-treatment, effect sizes comparable to those seen in the DORA key trials [14]. Patients switching from suvorexant to lemborexant (or vice versa) who have not completed a structured CBT-I program should receive a referral alongside any medication change.

Special Populations

Hepatic Impairment

Suvorexant is not recommended in severe hepatic impairment (Child-Pugh C) [1]. Lemborexant is also not recommended in severe hepatic impairment and requires dose reduction to a maximum of 5 mg in moderate impairment (Child-Pugh B) [2]. A patient switching from suvorexant to lemborexant who has Child-Pugh B liver disease must not exceed lemborexant 5 mg regardless of the efficacy rationale.

Renal Impairment

No dose adjustment is needed for either drug in mild-to-moderate renal impairment [1][2]. Severe renal impairment (eGFR <30 mL/min/1.73 m²) data are limited for both agents; use with caution and reassess frequently.

Pregnancy and Lactation

Neither drug has adequate human data in pregnancy. Animal studies for both show developmental toxicity at supra-therapeutic doses [1][2]. The prescriber and patient should weigh risks carefully. Lactation data are absent for both; the FDA labels advise against use in breastfeeding [1][2].